SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities, Brooke Army Medical Center And The United States Army Institute Of Surgical Research
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical Holding Corporation (NASDAQ:ICU) has expanded its NEUTRALIZE-AKI pivotal trial by adding Brooke Army Medical Center and the United States Army Institute of Surgical Research. The trial evaluates the safety and efficacy of SeaStar's Selective Cytopheretic Device (SCD) for treating acute kidney injury in ICU patients. The SCD has FDA Breakthrough Device Designation and CMS Category B coverage for certain expenses.
October 08, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SeaStar Medical has expanded its NEUTRALIZE-AKI trial by adding two military medical facilities, enhancing the trial's credibility and reach. The SCD device has FDA Breakthrough Device Designation and CMS coverage, potentially boosting investor confidence.
The expansion of the trial to include prestigious military medical facilities increases the trial's credibility and potential success. The FDA Breakthrough Device Designation and CMS coverage are positive regulatory developments that could enhance the company's market position and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100